I am a
Home I AM A Search Login

Papers of the Week

2019 Oct

J Neurol Neurosurg Psychiatry



Oral levosimendan in amyotrophic lateral sclerosis: a phase II multicentre, randomised, double-blind, placebo-controlled trial.


Al-Chalabi A, Shaw P, Leigh NP, van den Berg L, Hardiman O, Ludolph A, Aho VV, Sarapohja T, Kuoppamäki M
J Neurol Neurosurg Psychiatry. 2019 Oct; 90(10):1165-1170.
PMID: 31315908.


To evaluate the efficacy and safety of oral levosimendan in patients with amyotrophic lateral sclerosis (ALS). This phase II, randomised, double-blind, placebo-controlled, crossover, three-period study with 6 months open-label follow-up enrolled adults with ALS and sitting slow vital capacity (SVC) 60%-90 % of predicted from 11 sites in four countries.